The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates.

scientific article published on March 1996

The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P698PubMed publication ID8833052

P2093author name stringYelin E
P407language of work or nameEnglishQ1860
P921main subjectrheumatoid arthritisQ187255
P304page(s)47-51
P577publication date1996-03-01
P1433published inThe Journal of rheumatology. SupplementQ27711737
P1476titleThe costs of rheumatoid arthritis: absolute, incremental, and marginal estimates
P478volume44

Reverse relations

cites work (P2860)
Q50688343A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.
Q35240630A multicenter clinical trial in rheumatoid arthritis comparing silicone metacarpophalangeal joint arthroplasty with medical treatment
Q34398912A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings
Q92188732Analysis of the Indirect Costs of Rheumatoid Arthritis in Romania
Q36555104Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis.
Q35550292Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients
Q35780338Epidemiology and burden of illness of rheumatoid arthritis
Q34896078Epstein-Barr virus and rheumatoid arthritis: is there a link?
Q33684274Etanercept: a review of its use in rheumatoid arthritis
Q36843031Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out.
Q43492890Health-related quality of life in young adult patients with rheumatoid arthritis in Iran: reliability and validity of the Persian translation of the PedsQL™ 4.0 Generic Core Scales Young Adult Version.
Q35059538Immunosenescence and rheumatoid arthritis: does telomere shortening predict impending disease?
Q37172804Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group
Q40905089Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countries
Q36100671International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review
Q31019080Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial.
Q35555089Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity
Q42360360Sensory and vascular changes in a rat monoarthritis model: prophylactic and therapeutic effects of meloxicam
Q81478994The case for stratified cost-effectiveness analysis by baseline health-related QOL: theory and sensitivity analysis
Q53854537The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.
Q58025187The economic burden of rheumatoid arthritis: beyond health care costs
Q37251489The impact of rheumatoid arthritis and biologics on employers and payers.

Search more.